Dyax Corp.'s experimental drug DX-88 (ecallantide) met its goal of reducing symptoms of hereditary angioedema (HAE) in a second Phase III trial, sending shares of the firm up 15.5 percent Monday. (BioWorld Today)

Talecris Biotherapeutics Inc. said it is being acquired by Australian firm CSL Ltd. in a $3.1 billion cash merger that would form one of the largest plasma-derived therapeutics firms worldwide. (BioWorld Today)

Although top-line results of a Phase III efficacy trial showed that Altus Pharmaceuticals Inc.'s cystic fibrosis drug Trizytek (ALTU-135) hit its primary endpoint of improvement in fat absorption, the benefit was smaller than expected and results differed across various geographies. (BioWorld Today)

Celgene Corp. has ended its nearly three-year partnership with embattled German firm GPC Biotech AG on its prostate cancer drug satraplatin. (BioWorld Today)